Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Tait D ShanafeltXin V WangNeil E KayCurtis A HansonSusan O'BrienJacqueline BarrientosDiane F JelinekEsteban BraggioJose F LeisCong C ZhangSteven E CoutrePaul M BarrAmanda F CashenAnthony R MatoAvina K SinghMichael P MullaneRichard F LittleHarry ErbaRichard M StoneMark LitzowMartin TallmanPublished in: The New England journal of medicine (2019)
The ibrutinib-rituximab regimen resulted in progression-free survival and overall survival that were superior to those with a standard chemoimmunotherapy regimen among patients 70 years of age or younger with previously untreated CLL. (Funded by the National Cancer Institute and Pharmacyclics; E1912 ClinicalTrials.gov number, NCT02048813.).